{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:49:50Z","timestamp":1792507790293,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T00:00:00Z","timestamp":1578268800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T00:00:00Z","timestamp":1578268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s12185-019-02816-6","type":"journal-article","created":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T19:02:55Z","timestamp":1578337375000},"page":"559-566","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Poor prognostic impact of high serum ferritin levels in patients with a lower risk of diffuse large B cell lymphoma"],"prefix":"10.1007","volume":"111","author":[{"given":"Da Jung","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee-Yeong","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Cheol","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Sik","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho-Jin","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5974-6884","authenticated-orcid":false,"given":"Ho Sup","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,6]]},"reference":[{"key":"2816_CR1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1182\/asheducation-2006.1.295","volume":"2006","author":"LH Sehn","year":"2006","unstructured":"Sehn LH. Optimal use of prognostic factors in non-Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2006;2006:295\u2013302.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2816_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"M Shipp","year":"1993","unstructured":"Shipp M. International non-Hodgkin\u2019s lymphoma prognostic factors project. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;329:987\u201394.","journal-title":"N Engl J Med"},{"key":"2816_CR3","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857\u201361.","journal-title":"Blood"},{"key":"2816_CR4","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","volume":"123","author":"Z Zhou","year":"2014","unstructured":"Zhou Z, Sehn LH, Rademaker AW, Gordon LI, LaCasce AS, Crosby-Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837\u201342.","journal-title":"Blood"},{"key":"2816_CR5","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1093\/annonc\/mdp531","volume":"21","author":"A Bari","year":"2009","unstructured":"Bari A, Marcheselli L, Sacchi S, Marcheselli R, Pozzi S, Ferri P, et al. Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. Ann Oncol. 2009;21:1486\u201391.","journal-title":"Ann Oncol"},{"key":"2816_CR6","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A Rosenwald","year":"2002","unstructured":"Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937\u201347.","journal-title":"N Engl J Med"},{"key":"2816_CR7","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378:1396\u2013407.","journal-title":"N Engl J Med"},{"key":"2816_CR8","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1002\/cncr.31646","volume":"124","author":"PA Riedell","year":"2018","unstructured":"Riedell PA, Smith SM. Double hit and double expressors in lymphoma: definition and treatment. Cancer. 2018;124:4622\u201332.","journal-title":"Cancer"},{"key":"2816_CR9","unstructured":"Rosenwald A, Bens S, Advani R, Barrans S, Copie-Bergman C, Elsensohn M, et al. Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the lunenburg lymphoma biomarker consortium. J Clin Oncol. 2019; JCO1900743."},{"key":"2816_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ajh.2830090103","volume":"9","author":"Y Matzner","year":"1980","unstructured":"Matzner Y, Konijn A, Hershko C. Serum ferritin in hematologic malignancies. Am J Hematol. 1980;9:13\u201322.","journal-title":"Am J Hematol"},{"key":"2816_CR11","first-page":"102","volume":"13","author":"E Aulbert","year":"1990","unstructured":"Aulbert E, Steffens O. Serum ferritin\u2014a tumor marker in malignant lymphomas? Onkologie. 1990;13:102\u20138.","journal-title":"Onkologie"},{"key":"2816_CR12","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1073\/pnas.71.10.3956","volume":"71","author":"Z Eshhar","year":"1974","unstructured":"Eshhar Z, Order SE, Katz DH. Ferritin, a Hodgkin\u2019s disease associated antigen. Proc Natl Acad Sci USA. 1974;71:3956\u201360.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2816_CR13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/ijlh.12592","volume":"39","author":"S Koyama","year":"2017","unstructured":"Koyama S, Fujisawa S, Watanabe R, Itabashi M, Ishibashi D, Ishii Y, et al. Serum ferritin level is a prognostic marker in patients with peripheral T-cell lymphoma. Int J Lab Hematol. 2017;39:112\u20137.","journal-title":"Int J Lab Hematol"},{"key":"2816_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.clml.2013.09.008","volume":"14","author":"KA Yoh","year":"2014","unstructured":"Yoh KA, Lee HS, Park LC, Lee EM, Shin SH, Park DJ, et al. The prognostic significance of elevated levels of serum ferritin before chemotherapy in patients with non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2014;14:43\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2816_CR15","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.bbmt.2008.08.009","volume":"14","author":"A Mahindra","year":"2008","unstructured":"Mahindra A, Bolwell B, Sobecks R, Rybicki L, Pohlman B, Dean R, et al. Elevated ferritin is associated with relapse after autologous hematopoietic stem cell transplantation for lymphoma. Biol Blood Marrow Transpl. 2008;14:1239\u201344.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2816_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1080\/07853890500465189","volume":"38","author":"JW Verbsky","year":"2006","unstructured":"Verbsky JW, Grossman WJ. Hemophagocytic lymphohistiocytosis: diagnosis, pathophysiology, treatment, and future perspectives. Ann Med. 2006;38:20\u201331.","journal-title":"Ann Med"},{"key":"2816_CR17","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/art.23415","volume":"58","author":"L Fardet","year":"2008","unstructured":"Fardet L, Coppo P, Kettaneh A, Dehoux M, Cabane J, Lambotte O. Low glycosylated ferritin, a good marker for the diagnosis of hemophagocytic syndrome. Arthritis Rheum. 2008;58:1521\u20137.","journal-title":"Arthritis Rheum"},{"key":"2816_CR18","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1470-2045(08)70078-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Ho AD, Cavallin-Stahl E, Wolf M, Pettengell R, Vasova I, et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol. 2008;9:435\u201344.","journal-title":"Lancet Oncol"},{"key":"2816_CR19","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1182\/blood-2011-09-380949","volume":"119","author":"C M\u00fcller","year":"2012","unstructured":"M\u00fcller C, Murawski N, Wiesen MH, Held G, Poeschel V, Zeynalova S, et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood. 2012;119:3276\u201384.","journal-title":"Blood"},{"key":"2816_CR20","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1200\/JCO.2013.53.4537","volume":"32","author":"JT Bittenbring","year":"2014","unstructured":"Bittenbring JT, Neumann F, Altmann B, Achenbach M, Achenbach M, Ziepert M, et al. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. J Clin Oncol. 2014;32:3242\u20138.","journal-title":"J Clin Oncol"},{"key":"2816_CR21","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1200\/JCO.2011.39.2100","volume":"30","author":"KR Carson","year":"2012","unstructured":"Carson KR, Bartlett NL, McDonald JR, Luo S, Zeringue A, Liu J, et al. Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma. J Clin Oncol. 2012;30:3217\u201322.","journal-title":"J Clin Oncol"},{"key":"2816_CR22","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1200\/JCO.2010.29.4413","volume":"29","author":"MJ Maurer","year":"2011","unstructured":"Maurer MJ, Micallef IN, Cerhan JR, Katzmann JA, Link BK, Colgan JP, et al. Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. J Clin Oncol. 2011;29:1620\u20136.","journal-title":"J Clin Oncol"},{"key":"2816_CR23","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1080\/10428190802226425","volume":"49","author":"MC Cox","year":"2008","unstructured":"Cox MC, Nofroni I, Ruco L, Amodeo R, Ferrari A, La Verde G, et al. Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. Leuk Lymphoma. 2008;49:1745\u201351.","journal-title":"Leuk Lymphoma"},{"key":"2816_CR24","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.3109\/10428194.2014.893313","volume":"55","author":"LF Porrata","year":"2014","unstructured":"Porrata LF, Ristow KM, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, et al. Peripheral blood absolute lymphocyte\/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leuk Lymphoma. 2014;55:2728\u201338.","journal-title":"Leuk Lymphoma"},{"key":"2816_CR25","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s13277-012-0337-z","volume":"33","author":"Y Cao","year":"2012","unstructured":"Cao Y, Shi Y-X, Chen J-O, Tan Y-T, Cai Y-C, Luo H-Y, et al. Serum C-reactive protein as an important prognostic variable in patients with diffuse large B cell lymphoma. Tumour Biol. 2012;33:1039\u201344.","journal-title":"Tumour Biol"},{"key":"2816_CR26","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1200\/JCO.1989.7.10.1518","volume":"7","author":"F Swan Jr","year":"1989","unstructured":"Swan F Jr, Velasquez WS, Tucker S, Redman JR, Rodriguez MA, McLaughlin P, et al. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. J Clin Oncol. 1989;7:1518\u201327.","journal-title":"J Clin Oncol"},{"key":"2816_CR27","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/ncprheum0572","volume":"3","author":"E Dayer","year":"2007","unstructured":"Dayer E, Dayer J-M, Roux-Lombard P. Primer: the practical use of biological markers of rheumatic and systemic inflammatory diseases. Nat Clin Pract Rheumatol. 2007;3:512\u201320.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"2816_CR28","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/265755a0","volume":"265","author":"JT Hazard","year":"1977","unstructured":"Hazard JT, Drysdale JW. Ferritinaemia in cancer. Nature. 1977;265:755\u20136.","journal-title":"Nature"},{"key":"2816_CR29","first-page":"297","volume":"86","author":"E Aulbert","year":"1991","unstructured":"Aulbert E, Fromm H, Hornemann H. Ferritin in acute leukemia. Serum ferritin concentration as a nonspecific tumor marker for M1 and M2 myeloid leukemia. Med Klin (Munich). 1991;86:297\u2013304.","journal-title":"Med Klin (Munich)"},{"key":"2816_CR30","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1182\/blood-2006-10-054924","volume":"109","author":"P Armand","year":"2007","unstructured":"Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 2007;109:4586\u20138.","journal-title":"Blood"},{"key":"2816_CR31","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/1097-0142(19860115)57:2<305::AID-CNCR2820570219>3.0.CO;2-D","volume":"57","author":"PE Maxim","year":"1986","unstructured":"Maxim PE, Veltri RW. Serum ferritin as a tumor marker in patients with squamous cell carcinoma of the head and neck. Cancer. 1986;57:305\u201311.","journal-title":"Cancer"},{"key":"2816_CR32","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1007\/s13277-012-0426-z","volume":"33","author":"M Kalousov\u00e1","year":"2012","unstructured":"Kalousov\u00e1 M, Krechler T, J\u00e1chymov\u00e1 M, Kub\u011bna AA, \u017d\u00e1k A, Zima T. Ferritin as an independent mortality predictor in patients with pancreas cancer Results of a pilot study. Tumour Biol. 2012;33:1695\u2013700.","journal-title":"Tumour Biol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02816-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-019-02816-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02816-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T00:52:13Z","timestamp":1609807933000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-019-02816-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,6]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["2816"],"URL":"https:\/\/doi.org\/10.1007\/s12185-019-02816-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,6]]},"assertion":[{"value":"23 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the Declaration of Helsinki (1964) and its later amendments or comparable ethical standards. According to the Declaration of Helsinki, the trial was approved by the Institutional Research Ethics Board of Kosin University Gospel Hospital, which waived the requirement for informed consent given the retrospective nature of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}